| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Minocycline HCl (NSC 141993; Periocline; Klinomycin; Minocin; Solodyn; Minocin), the hydrochloride salt of minocycline, is a potent, oral and broad-spectrum tetracycline antibiotic used to treat a number of bacterial infections such as pneumonia. It is generally less preferred than the tetracycline doxycycline. It is also used for the treatment of acne and rheumatoid arthritis. It acts by binding to the bacterial 30S ribosomal subunit and inhibiting protein synthesis.
| ln Vitro |
OVCAR-3, SKOV-3, and A2780 pearl cotton lines are inhibited in terms of proliferation and clonogenic activity by minocycline hydrochloride (0-100 μM, 24-72 hours) [3]. Hydrochloride of minocycline (0-100 μM, 24-48 hours). In an oscilloscope, minocycline hydrochloride (0-100 μM, 72 h)) causes a cell cycle [3]. In addition to inhibiting both caspase-dependent and caspase-independent cell death, direct neural protection may also be linked to mitochondrial abnormalities and cytochrome c protection [2]. Examination of the proliferation of hypoxia-inducible factor (HIF) cells induced by minocycline hydrochloride [3]
|
|---|---|
| ln Vivo |
In female nude mice, ovccrine hydrochloride (0–30 mg/kg) administered intravenously once daily for four weeks inhibits the growth of OVCAR-3 tumors [3]. In animal models of brain damage, minocycline hydrochloride (IP), a powerful medication, exhibits neuroprotective effects when administered intraperitoneally in high dosages [1]. METH-induced hyperlocomotion and behavioral sensitization in mice are markedly inhibited by minocycline hydrochloride (0–40 mg/kg, IP, once) [2]. In a model of temporary middle cerebral artery occlusion (TMCAO), minocycline hydrochloride (3 and 10 mg/kg IV once) effectively reduces infarct size [1]. The effects of minocycline hydrochloride (3–10 mg/kg IV once) on blood may be mitigated by potential-induced ventricular arrhythmias. This effect in humans at the standard 200 mg dose may be associated with mitochondrial KATP channels, PI3K/Akt signaling, and L-type levels (3 mg/kg) [1].
|
| Cell Assay |
Cell Proliferation Assay[3]
Cell Types: human ovarian cancer cell line (OVCAR-1α inhibition, and regulation of up-p53 protein and AKT levels/mTOR/p70S6K/ Inactivation of 4E-BP1 dye [6]. 3. SKOV-3 and A2780) and primary cells (HEK-293, HMEC, HUVEC, ATCC) Tested Concentrations: 0, 1, 10, 50 and 100 μM Incubation Duration: 24 , 48 or 72 hrs (hours) Experimental Results: Inhibition of the proliferation of OVCAR-3, SKOV-3 and A2780 cells was concentration-dependent, with IC50 values of 62.0, 56.1 and 59.5 μM respectively. There was no effect on the viability of HEK-293 or HUVEC. Western Blot Analysis[3] Cell Types: OVCAR-3, SKOV-3 and A2780 Cell Tested Concentrations: 0, 10, 50 and 100 μM Incubation Duration: 72 hrs (hours) Experimental Results: Cyclins A, B and E were expressed at low levels. caspase- increasing by 3 levels increased more than 3.0-fold at 100 μM. Minocycline-activated caspase-3 in turn leads to the cleavage of PARP-1. Caspase-3 increases the degradation product of PARP-1, p89. Cell cycle analysis[3] Cell Types: OVCAR-3, SKOV-3 and A2 |
| Animal Protocol |
Animal/Disease Models: Female nude mice (6 weeks old, 9 mice per group, each mouse was injected with OVCAR-3 cells subcutaneously (sc) (sc) on the left side of the abdomen) [3]
Doses: 10 or 30 mg/kg Route of Administration: Orally in drinking water Administration, starting on day 8 of cell inoculation, one time/day for 4 weeks. Experimental Results: Inhibited OVCAR-3 tumor growth and diminished microvessel density in these female nude mice. Animal/Disease Models: Male Balb/cAnNCrICrIj mice (8 weeks old, 23-30 g, methamphetamine (METH, 3 mg/kg) subcutaneously (sc) (sc) (sc) in a volume of 10 ml/kg) [2] Doses: 0, 10 , 20 or 40 mg/kg Route of Administration: intraperitoneal (ip) injection, once, 30 minutes before METH administration Experimental Results: Significantly attenuated METH-induced hyperlocomotion and the development of behavioral sensitization in mice at 40 mg/kg. Did not exert any effect on the induction of METH-induced hyperthermia in mice. Significantly attenuated the reduction of DA and DOPAC in the striatum. Significantly attenuated the reduction of DAT-immunoreactivity in the mouse striatum. Significantly attenuated the increase in MAC1-immunoreactivity in the striatum after the administration of METH. Animal/Disease Models: Male Sprague-Dawley rats (270-330 g, TMCAO model)[1] Doses: 3 mg/kg and 10 mg/kg Route of Administration: IV, once, 4, 5, or 6 hours post TMCAO Experimental Results: Reduced infarct size by 42% while 10 mg/kg reduced infarct size by 56% at doses of 3 mg/kg; significantly reduced infarct size at 5 hours by 40% at doses of 10 mg/kg and the 3 mg/kg dose significantly reduced infarct size by 34%. With a 6 hour time window there was a non-significant trend in infarct reduction. Animal/Disease Models: Male Sprague-Dawley rats (270-330 g)[1] Doses: 3, 10, or 20 mg/kg Route of Administration: IV, once Experimental Results: Peak concentrations of serum levels of minocycline averaged 3.6, 13.0 and 28.8 mg/L with 3, 10 and 20 mg/kg doses respectively. The serum levels of minocycline at a 3 mg/kg dose (3.6 mg/L) were similar to that reported in humans after a standard 200 mg dose. Did not significantly affect hemodynamic and physiological variables. |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation Many reviews state that tetracyclines are contraindicated during breastfeeding because of possible staining of infants' dental enamel or bone deposition of tetracyclines. However, a close examination of available literature indicates that there is not likely to be harm in short-term use of minocycline during lactation because milk levels are low and absorption by the infant is inhibited by the calcium in breastmilk. Short-term use of minocycline is acceptable in nursing mothers. As a theoretical precaution, avoid prolonged or repeat courses during nursing. Monitor the infant for rash and for possible effects on the gastrointestinal flora, such as diarrhea or candidiasis (thrush, diaper rash). Black discoloration of breastmilk has been reported with minocycline. Topical minocycline for acne by the mother poses no risk to the breastfed infant. ◉ Effects in Breastfed Infants Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk A woman taking minocycline 100 mg twice daily for almost 4 years developed galactorrhea after taking perphenazine, amitriptyline and diphenhydramine, and the breast secretion was black in color. Another woman who had nursed her infant and produced occasional small amounts of breastmilk during the 18 months after weaning was given oral minocycline 150 mg daily. After 3 to 4 weeks, expressed milk had become black. Iron levels in milk were over 100 times greater than that found in normal milk. A mammogram was normal. In both of these cases, macrophages containing a black, iron-containing pigment were found in milk. It is thought that the pigment is an iron chelate of minocycline or one of its metabolites. |
| References |
|
| Additional Infomation |
Minocycline Hydrochloride (internal use) can cause developmental toxicity according to state or federal government labeling requirements.
A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections. See also: Minocycline Hydrochloride (annotation moved to). |
| Molecular Formula |
C23H28CLN3O7
|
|---|---|
| Molecular Weight |
493.9373
|
| Exact Mass |
493.161
|
| CAS # |
13614-98-7
|
| Related CAS # |
Minocycline;10118-90-8
|
| PubChem CID |
54685925
|
| Appearance |
Light yellow to yellow solid powder
|
| Boiling Point |
659.4ºC at 760mmHg
|
| Melting Point |
205-210° (dec)
|
| Flash Point |
352.6ºC
|
| Vapour Pressure |
6.33E-28mmHg at 25°C
|
| LogP |
1.688
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
34
|
| Complexity |
971
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C.Cl
|
| InChi Key |
KDLQIOPKJDNQIM-YKWOUSISSA-N
|
| InChi Code |
InChI=1S/C23H27N3O7.ClH/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28;/h5-6,9,11,17,27-28,32-33H,7-8,24H2,1-4H3;1H/b22-16+;/t9-,11-,17+,23-;/m1./s1
|
| Chemical Name |
(4S,4aR,5aS,12aR,E)-2-(amino(hydroxy)methylene)-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5a,6,12a-tetrahydrotetracene-1,3,12(2H,4H,5H)-trione hydrochloride
|
| Synonyms |
NSC 141993; Minocycline HCl; NSC 141993; Mynocine hydrochloride; NSC141993; NSC-141993; Periocline; Klinomycin; Minocin; Solodyn; Mynocine; Tri-mino; Vectrin; Ximino; Minomax; Minomycin chloride; Mynocine hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~19.23 mg/mL (~38.93 mM)
H2O : ~9.09 mg/mL (~18.40 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 7.69 mg/mL (15.57 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0245 mL | 10.1227 mL | 20.2454 mL | |
| 5 mM | 0.4049 mL | 2.0245 mL | 4.0491 mL | |
| 10 mM | 0.2025 mL | 1.0123 mL | 2.0245 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA